Korean J Intern Med.  2002 Dec;17(4):259-262.

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer

• Min YJ
• Joo KR
• Park NH
• Yun TK
• Nah YW
• Nam CW
• Park JH

Abstract

BACKGROUND: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer. METHODS: Seventeen chemotherapy-na ve patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks. RESULTS: The median age of patients was 55 years (range 44~82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3~4 toxic side effect was leucopenia only (29%) and was easily managed without infection. CONCLUSION: Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.

Keyword

Pancreatic Cancer; Gemcitabine

MeSH Terms

Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic/*therapeutic use
Deoxycytidine/*analogs & derivatives/*therapeutic use
Female
Human
Male
Middle Aged
Pancreatic Neoplasms/*drug therapy/*mortality/pathology
Retrospective Studies
Ribonucleotide Reductases/antagonists & inhibitors
Survival Rate